Long-Acting Early Viral Inhibition Described in Context of Long-Acting Injectable Cabotegravir
By Elana Gotkine HealthDay Reporter
MONDAY, July 29, 2024 -- In a research letter published online July 24 in the New England Journal of Medicine, the authors describe long-acting early viral inhibition (LEVI) among patients with acute HIV infection in the context of long-acting injectable cabotegravir (CAB-LA) preexposure prophylaxis (PrEP). The research was published to coincide with the 25th International AIDS Conference, held from July 22 to 26 in Munich.
Noting that in the HIV Prevention Trials Network (HPTN) 083 and 084 trials, altered presentation of acute HIV infection in the context of CAB-LA PrEP, LEVI was observed, Raphael J. Landovitz, M.D., from the University of California in Los Angeles, and colleagues examined presentations of HIV infection involving LEVI and classic HIV infection.
The authors note that cases involving LEVI were characterized by low or undetectable HIV viral load and reduced or delayed antibody production, and were usually clinically silent. HIV antigens, antibodies, RNA, and DNA levels were often near the level of detection of available assays, which may revert from reactive, indeterminate, or positive to nonreactive or negative, challenging confirmation of HIV. Forty-one HIV infections were identified among 3,446 participants who had been randomized to receive CAB-LA in trials HPTN 083 and 084; detection of an infection was delayed in 17 (41 percent) when an HIV rapid test and a HIV antigen and antibody test were used for screening.
"When interpreting HIV test results in persons who are receiving CAB-LA PrEP, providers should recognize that a prolonged period of observation with frequent retesting may be needed before infection can be confirmed or ruled out," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including ViiV Healthcare and Gilead Sciences, which donated trial medications and matching placebos. ViiV Healthcare provided additional funding.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Funding Reductions Could Reverse Progress in HIV Response
THURSDAY, March 27, 2025 -- Funding reductions could reverse progress in the HIV response by 2030, with the greatest effects anticipated in countries with a higher percentage of...
Recommendations Provided for Treating, Preventing HIV
FRIDAY, Dec. 27, 2024 -- In a special communication issued by the International Antiviral Society-USA Panel and published online Dec. 1 in the Journal of the American Medical...
Incidence of HIV Lower With Twice-Yearly Subcutaneous Lenacapavir
TUESDAY, Dec. 3, 2024 -- In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.